The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.Print ISSN: 0732-183X
《临床肿瘤学杂志》为读者提供了传播重要临床肿瘤学研究的唯一最可信、最权威的资源。JCO致力于以印刷和电子形式发表最高质量的临床研究文章。原始报告仍然是JCO的重点，但通过适当选择社论、评论、综述和其他与癌症患者护理相关的工作，这种科学交流得到了加强。打印ISSN：小行星0732- 183 X
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.129
The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.581
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.8516
Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.637
Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.8003
Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.483
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.5541
A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.3127
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.524
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.241
Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.10053
External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E18005
Safety and efficacy of nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy for locally advanced cervical squamous cell cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.5532
Racial disparities in radium-223 treatment in a large real-world population.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.268
From presentation to paper: Gender disparities in oncological research.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.10523
A novel anti-CD19 chimeric T cell therapy platform ET019002 was safe and effective in inducing CR in blast crisis of CML: A case study.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E18540
Combined radiotherapy and transarterial chemoembolization as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.452
Effect of smoking on the efficacy of immune checkpoint inhibitors in advanced cancers: A systematic review and meta-analysis.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E14109
HIF1A genetic variability and late adverse events of radiotherapy in breast cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E12069
A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.8_SUPPL.96
Lack of clinician knowledge of human papillomavirus (HPV) vaccination to prevent HPV-related cancers in men: An interview study.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E18273
The impact of muscle mass loss after esophagectomy for esophageal cancer on prognosis.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.107
Health care utilization associated with adverse events (AEs) among metastatic non-small cell lung cancer (mNSCLC) patients treated with immunotherapy or chemotherapy.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E20655
Using PIK3CB and connexin-43 inhibition to sensitize pediatric glioblastoma cells to temozolomide.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E13572
Barriers to minority recruitment in a multicenter clinical trial (PRO-TECT [AFT-39]): Research staff insights.
来源期刊：Journal of Clinical OncologyDOI：10.1200/jco.2019.37.27_suppl.145
Neoadjuvant chemotherapy versus upfront resection in ampullary adenocarcinoma stratified by stage: A retrospective analysis using the National Cancer Database.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.318
Outcomes of tbo-filgrastim, filgrastim-sndz or filgrastim for mobilization in patients undergoing an autologous hematopoietic stem cell transplant: A single center experience.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E19000
Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.TPS3159
Unique racial patterns in rare T-cell lymphomas: A National Cancer Registry analysis from 2001 to 2015.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E19070
A prospective study of robotic rectal surgery for carcinoma rectum assessing the functional and oncological outcomes: Hype or hope?
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.661
Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E15130
Building international partnerships to improve global oncological care: Perspective from Rutgers-CINJ Global Oncology Fellowship Program.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E18161
Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.9590
Temporal trends and disease characteristics associated with total neoadjuvant therapy (TNT) usage.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.642
Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.3053
Re-examining an old trend: The association of human papillomavirus and bladder cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.362
Patient related outcomes in cancer patients in Croatia.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.TPS6650
Patient-reported distress and symptoms predict post-esophagectomy outcomes.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E15567
Antiviral therapy to reduce hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.1510
The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.419
Assessment of the diagnostic value of microsatellite instability in the urine of bladder cancer patients.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.7_SUPPL.384
Do oral antineoplastic treatment data differ between Concerto Health AI Definitive Oncology EMR and Symphony Claims Data
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E18180
Relationship of emergency department use pre- and post-cancer diagnosis in safety-net adults.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.6626
Patient and disease characteristics of colorectal cancer in a cohort of young patients.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_SUPPL.513
Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E15760
A general approach to optimizing tumor treating fields therapy.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E14668
Incidence of pulmonary metastasis among patients with colorectal adenocarcinoma: Correlation between sidedness and RAS mutations.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.4_suppl.527
Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.E14568
Racial comparisons in receipt of timely guideline-based colon cancer treatment in an equal-access health system.
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.6563
Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
来源期刊：Journal of Clinical OncologyDOI：10.1200/JCO.2019.37.15_SUPPL.3015
